About

​

 

AlloCyte Pharmaceuticals AG is a Swiss biotech company developing oral allosteric integrin modulators to protect organs from tissue-destructive autoimmune diseases. The company's next milestone is clinical proof-of-concept in a high-priority autoimmune disease.  

​​

 

The Need

​

Autoimmune diseases affect 5–8% of the global population, and their prevalence is rising. Despite major advances in immune modulation, there is no oral therapy to effectively and selectively stop the immune system from destroying healthy tissue. AlloCyte was founded to change this.

​

​

The Game Change

​

AlloCyte is developing oral allosteric integrin modulators to restore the immune receptor balance disrupted in tissue-destructive autoimmune diseases. Our fully owned, patent-protected platform has demonstrated oral efficacy proof-of-principle, excellent tolerability and favorable pharmacokinetics across preclinical studies. Translational bridging studies in biomaterials of patients with active disease confirmed the intended effect profile, supporting advancement toward clinical proof-of-concept.

 

​

Team of Competency

​

​Founded by leaders in immunology drug development, AlloCyte combines deep scientific, drug development and clinical expertise with strong academic and industry partnerships. Supported by public, private, and corporate funding, the company is advancing its oral lead program toward clinical proof-of-concept.

​